Skip to main content

Phase 3 Readout

TAK: Phase 3 Topline: A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line T

October 31, 2026 · non-small. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
October 31, 2026
Company
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Drug
non-small
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line T

TAK overview →
Drug
non-small
Indication
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Other upcoming events for TAK

Phase 2 StartPhase 2 Start: A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety an
Phase 3 ReadoutPhase 3 Topline: A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety